Most important in brief
- CT, PET-CT and a brain MRI show how far the cancer has spread.
- A biomarker test looks in the tumour for features such as EGFR, ALK, KRAS G12C and PD-L1.
- The result helps decide whether a targeted tablet or immunotherapy is suitable.
- For advanced NSCLC, guidelines recommend testing several markers together, often with NGS.
- Usually tissue from a biopsy is tested. A blood test can sometimes add information, and when a tablet stops working, testing is often repeated.
- Only your care team can interpret your result. Bring your report and ask.
This page explains non-small cell lung cancer (NSCLC). Small cell lung cancer is tested and treated differently. Everything about it on its own page →
Tests for the stage
First it is worked out how far the cancer has spread. That decides whether surgery or radiotherapy aimed at cure is an option.
| Test | What it is for |
|---|---|
| CT and PET-CTBefore treatment | Show how far it has spread. |
| Brain MRIBefore treatment | Looks for spread to the brain, before treatment and at check-ups. |
| Lymph node sample (EBUS)Before treatment | Checks lymph nodes in the middle of the chest, often before surgery. |
| Lung function and heartBefore treatment | Show whether surgery would be well tolerated. |
Why is the tumour tested?
Not every lung cancer is the same. A biomarker test looks in the tumour for features that can matter for treatment, such as PD-L1 and gene changes like EGFR, ALK or KRAS G12C. For advanced NSCLC, professional guidelines recommend testing several markers together where possible, often with NGS (ESMO; Onkopedia).
What your result can mean
This table shows the main markers in advanced NSCLC and what they can mean for treatment. Your care team will tell you what applies to you and what is available in your country.
| Result | What it is | What it can mean for treatment |
|---|---|---|
| EGFR | Mutation, about 1 in 7 in Europe | Targeted tablets, usually as the very first treatment, also after surgery. |
| ALK | Gene fusion, about 3 to 5 in 100 | Targeted tablets as the first treatment, also after surgery. |
| ROS1 | Gene fusion, about 1 to 2 in 100 | Targeted tablets as the first treatment. |
| KRAS G12C | Mutation, about 1 in 7 | Targeted tablets, in the EU after a first treatment. |
| BRAF V600E | Mutation, about 1 to 2 in 100 | Two tablets together, often as the first treatment. |
| MET exon 14 | Change (exon 14 skipping), about 3 in 100 | Targeted tablets, in the EU after a first treatment. |
| RET | Gene fusion, about 1 to 2 in 100 | Targeted tablet, often as the first treatment. |
| NTRK | Gene fusion, fewer than 1 in 100 | Tablets authorised for any cancer with this fusion. |
| HER2 | Mutation, about 2 to 3 in 100 | An antibody medicine, in the EU after a first treatment. |
| Other KRAS forms | Mutation | No authorised tablet yet. Treated as if no change was found. |
| PD-L1 | A protein on tumour cells, given as a percentage | Helps choose immunotherapy. 50% or more: also possible alone. 1 to 49%: usually together with chemo. Below 1%: possible with chemo; some immunotherapies require at least 1%. |
| None of these changes | Common | Usually immunotherapy, often together with chemotherapy. |
Simplified, as of November 2026, based on the ESMO and Onkopedia guidelines. Frequencies are for people with NSCLC in Europe.
Usually only one of these changes is found, rarely two. The team then discusses which one counts first for treatment.
Changes found in about 4 in 100 people with NSCLC or more have their own page: EGFR, KRAS G12C, ALK. ROS1 shares the ALK page because it is very similar.
All others are explained in the same way on the Rarer changes page.
What kinds of test are there?
The test is done on a sample, and there are two ways of reading it. Your report says which were used for you.
| Type | What is tested | Good to know |
|---|---|---|
| Tissue sample (biopsy) | A small piece of tumour tissue | The usual way to test. |
| Blood sample (liquid biopsy) | Traces of the tumour in the blood | No new biopsy needed. If it finds nothing, there may still be something in the tissue. |
| Single-gene test | One gene or one feature | Several markers need several tests, so more tissue and time. |
| NGS panel | Many genes at once | Saves tissue and time when several markers are needed. |
Tests at an early stage
Even when surgery is possible, biomarkers matter: with EGFR or ALK a tablet after surgery is an option, and immunotherapy beforehand then helps less. The PD-L1 level can matter for immunotherapy before or after surgery. Ask whether these tests were done, ideally before surgery.
A new test when treatment stops working
When a targeted tablet stops working, testing is often repeated, from tissue or blood. The test shows what has changed in the tumour, which decides what may help next.
| Test | What it is for |
|---|---|
| New test when the tablet stops workingDuring and after treatment | Tissue or blood shows what has changed and what may help next. |
| Blood test (liquid biopsy)Ask about it | Finds tumour DNA in the blood when there is not enough tissue or speed matters. |
Reading your report: an example
Reports are often hard to read. This made-up example shows where the important details usually are. Each line comes with what it means.
Example · not a real reportMolecular pathology report
| In the report | Example | What it means |
|---|---|---|
| Specimen | Tumour tissue, lung biopsy | Where the sample came from: tissue from a biopsy or operation, or blood. |
| Diagnosis | Adenocarcinoma of the lung (NSCLC) | The type of lung cancer. NSCLC is the umbrella term, adenocarcinoma the most common form. |
| Method | NGS panel, 50 genes | How the test was done. “NGS” or “panel” means many genes at once. |
| KRAS | p.G12C (c.34G>T)detected | The change was found. “p.G12C” and “c.34G>T” are two technical ways of writing the same change. |
| EGFR, ALK, ROS1 | not detected | These changes were not found. That is an important result too. |
| PD-L1 (TPS) | 30% | Share of tumour cells carrying the protein PD-L1. Your team will explain what the value means for you. |
Only your care team can say what your result means for your treatment. Take the report to your appointment and mark anything you don’t understand.
Questions to ask about tests
Why ask?
If a marker is missing, a matching treatment can be overlooked.
Why ask?
A single-gene test finds only what it looked for; a panel also finds rare changes.
Why ask?
If there is not enough, a blood test or a new biopsy may be needed, which takes time.
Why ask?
Then you know what you are waiting for and whom to contact.
Why ask?
Not every test is paid for everywhere; this can be cleared up beforehand.
